Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.62 |
| ▸ | RAB9A | P51151 | 10/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189871 | 0.86 | CRHR1 (0.47) | MAPTRAB9AKDM4EALDH1A1CRHR1 | |
| SCHEMBL5786298 | 0.77 | MAPT (0.61) | MAPTRAB9AKDM4EALDH1A1CRHR1 | |
| SCHEMBL3198742 | 0.76 | CRHR1 (0.54) | MAPTRAB9AKDM4EALDH1A1CRHR1 | |
| SCHEMBL31465393 | 0.76 | KDM4E (0.59) | MAPTRAB9AKDM4EALDH1A1CRHR1 | |
| SCHEMBL11931415 | 0.75 | RAB9A (0.76) | MAPTRAB9AKDM4EALDH1A1NPC1 | |
| SCHEMBL5872518 | 0.75 | CRHR1 (0.58) | MAPTRAB9AKDM4EALDH1A1CRHR1 | |
| SCHEMBL19455177 | 0.73 | MAPT (0.59) | MAPTRAB9AKDM4EALDH1A1NPC1 | |
| SCHEMBL16946660 | 0.70 | MAPT (0.77) | MAPTRAB9AKDM4EALDH1A1NPC1 | |
| SCHEMBL12953199 | 0.70 | MAPT (0.56) | MAPTRAB9AKDM4EALDH1A1NPC1 | |
| SCHEMBL11507014 | 0.70 | NPC1 (0.46) | RAB9ANPC1HPGDNPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678793-B2 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1908764-A1 | Azolo triazines and pyrimidines | Bristol-Myers Squibb Pharma Company (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-0915880-B1 | AZOLO TRIAZINES AND PYRIMIDINES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20060252756-A1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY. | 2006-11-09 | — | — | US | disclosed |
| US-7094782-B1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1344779-B1 | Azolo-pyrimidines | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1344779-A1 | Azolo-pyrimidines | Bristol-Myers Squibb Pharma Company (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030008885-A1 | Azolo triazines and pyrimidines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-6358950-B1 | ADMINISTERING (1,5-A)-PYRAZOLO-1,3,5-TRIAZINE DERIVATIVES AS ANXIOLYTIC AGENTS AND ANTIDEPRESSANTS; CORTICOTROPIN RELEASING FACTOR ANTAGONISTS; CARDIOVASCULAR, AUTOIMMUNE, NERVOUS SYSTEM, EATING, AND PSYCHOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313124-B1 | AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS USED FOR THERAPY OF ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC, NEUROLOGICAL DISORDERS AS WELL AS TREATMENT OF IMMUNOLOGICAL, CARDIOVASCULAR OR HEART-RELATED DISEASES | DUPONT PHARMACEUTICALS COMPANY | 2001-11-06 | — | — | US | disclosed |
| US-6191131-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-20 | — | — | US | disclosed |
| US-6136809-A | (1,5-A)-PYRAZOLO-PYRIMIDINES AND (1,5-A)-1,2,3-TRIAZOLO-PYRIMIDINES FOR TREATMENT OF CARDIOVASVULAR DISORDERS, STRESS AND PSYCHOLOGICAL DISORDERS WITH CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST | DUPONT PHARMACEUTICALS (US) | 2000-10-24 | — | — | US | disclosed |
| US-6124289-A | TREATING ANXIETY OR DEPRESSION IN MAMMALS | DUPONT PHARMACEUTICALS CO. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6060478-A | ANTIDEPRESSANTS | DUPONT PHARMACEUTICALS (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0915880-A1 | AZOLO TRIAZINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998003510-A1 | AZOLO TRIAZINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252756-A1 | Azolo triazines and pyrimidines | CRH, CRHR1, CRHR2 | MAPT 2671/4885RAB9A 4229/4885KDM4E 4689/4885 |
| US-20030008885-A1 | Azolo triazines and pyrimidines | CRH, CRHR1, CRHR2 | MAPT 2786/4885RAB9A 4323/4885KDM4E 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.